Food allergy venture to boost ALK's growth

In future years, allergy company ALK will go all-in on winning the billion-dollar (US) food allergy market, which in spite of a sparse customer base is many times the size of the respiratory allergy market in which ALK has previously placed stakes.

Photo: ALK / PR

Things are going well for Danish allergy company ALK, which develops and sells immunotherapies for allergies caused by triggers such as house dust mites, pollen and grass.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

China approves Y-mabs drug

Y-mabs’ cancer treatment Danyelza, which is currently licensed to Sciclones, has been approved by the Chinese authorities. Y-mabs will receive double-digit sales royalties.

Further reading

Related articles

Latest news

See all jobs